Literature DB >> 30765453

Bilateral osteonecrosis of the hip in panhypopituitarism.

Jasmene Uppal1, Brent Burbridge2, Terra Arnason1.   

Abstract

Osteonecrosis, also known as avascular necrosis, is a condition that causes significant morbidity and loss of function. It is a common complication seen with supraphysiological steroid use. Early diagnosis is critical as it impacts prognosis. We report a 20-year-old man who developed bilateral osteonecrosis of the hip following 6 years of low-dose steroid replacement therapy for panhypopituitarism secondary to a transsphenoidal resection of a growth hormone-secreting pituitary macroadenoma. The patient presented with several weeks of right-sided hip pain and significant loss of function. X-ray and MRI showed bilateral osteonecrosis of the hips with the right side more severely affected than the left. He was initiated on analgesics and bisphosphonates and underwent right hip total arthroplasty followed 1 year later by left hip arthroplasty. Postsurgery, the patient is mobilising well and his pituitary hormones are well balanced. He continues on low-dose glucocorticoid replacement which will continue lifelong. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  drugs: endocrine system; pituitary disorders; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2019        PMID: 30765453      PMCID: PMC6382027          DOI: 10.1136/bcr-2018-227471

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

Review 1.  In brief: Ficat classification: avascular necrosis of the femoral head.

Authors:  Muhammad Umar Jawad; Abdul Ahad Haleem; Sean P Scully
Journal:  Clin Orthop Relat Res       Date:  2012-09       Impact factor: 4.176

2.  Glucocorticoid-induced osteoporosis: treatment update and review.

Authors:  Lisa-Ann Fraser; Jonathan D Adachi
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

3.  Spontaneous resolution of osteonecrosis of the femoral head.

Authors:  Edward Y Cheng; Issada Thongtrangan; Alan Laorr; Khaled J Saleh
Journal:  J Bone Joint Surg Am       Date:  2004-12       Impact factor: 5.284

Review 4.  Steroid induced osteonecrosis: An analysis of steroid dosing risk.

Authors:  Christian Powell; Christopher Chang; Stanley M Naguwa; Gurtej Cheema; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2010-07-09       Impact factor: 9.754

Review 5.  Current concepts on osteonecrosis of the femoral head.

Authors:  Joaquin Moya-Angeler; Arianna L Gianakos; Jordan C Villa; Amelia Ni; Joseph M Lane
Journal:  World J Orthop       Date:  2015-09-18

Review 6.  Corticosteroid-associated avascular necrosis: dose relationships and early diagnosis.

Authors:  Roy K Aaron; Anne Voisinet; Jennifer Racine; Yousaf Ali; Edward R Feller
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

7.  Osteonecrosis following short-term, low-dose oral corticosteroids: a population-based study of 24 million patients.

Authors:  Matthew F Dilisio
Journal:  Orthopedics       Date:  2014-07       Impact factor: 1.390

8.  Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone.

Authors:  D T Felson; J J Anderson
Journal:  Lancet       Date:  1987-04-18       Impact factor: 79.321

Review 9.  Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action.

Authors:  Mohammad Amin Kerachian; Chantal Séguin; Edward J Harvey
Journal:  J Steroid Biochem Mol Biol       Date:  2009-02-21       Impact factor: 4.292

10.  Spontaneous resolution of avascular necrosis of femoral heads following cure of Cushing's syndrome.

Authors:  A Pazderska; S Crowther; P Govender; K C Conlon; M Sherlock; J Gibney
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-05-01
View more
  1 in total

1.  Outcomes of Total Hip Arthroplasty in Patients with Osteonecrosis of the Femoral Head Following Surgical Treatment of Brain Tumors.

Authors:  Seung-Jae Lim; Chan-Woo Park; Dong-Uk Kim; Kwangjoon Han; Minkyu Seo; Young-Wan Moon; Jung-Il Lee; Youn-Soo Park
Journal:  J Clin Med       Date:  2019-10-16       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.